Hatch and mail order
The Pharmaceutical Care Management Association and Merck-Medco have contacted Sen. Hatch's (R-Utah) office to discuss concerns about mail order pricing aired by Hatch during a Senate Finance Committee hearing on Medicare drug coverage April 24. "I know of certain circumstances where it is significantly cheaper to get the 30-day prescription filled [at retail] than it is to order a three-month supply through a mail-order plan," Hatch said, displaying a staffer's receipts for generic tetracycline, which cost $1.45 to fill at retail and $12 for a three-month mail supply. "I'm a strong supporter of PBMs, but I also believe that these are important questions that need to be addressed"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth